generation run 2026-05-11
60 min completedmodel pipeline-v5plan not recordedrun/954ed28e…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
4 further caveats recorded as free text — readable on the working page
Reproduce
- inputs
- 32 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
13 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubChem | THCV | 1 | 1 | Primary chemical identity source |
| 2 | PubMed | THCV tetrahydrocannabivarin pharmacology receptor binding | 14 | 14 | All directly relevant to THCV pharmacology, mechanism, and therapeutic applications |
| 3 | OpenAlex | tetrahydrocannabivarin THCV cannabinoid receptor | 846 | 3 | High-citation landmark papers directly focused on THCV pharmacology |
| 4 | ClinicalTrials.gov | tetrahydrocannabivarin THCV | 5 | 5 | All relevant trials testing THCV in clinical populations |
| 5 | PubMed | tetrahydrocannabivarin neuroprotection Parkinson's disease | 2 | 2 | Both directly relevant to THCV neuroprotection in Parkinson's disease |
| 6 | PubMed | THCV tetrahydrocannabivarin obesity appetite diabetes metabolic | 3 | 3 | Relevant reviews and primary research on THCV metabolic effects |
| 7 | PubMed | THCV tetrahydrocannabivarin GWP42004 type 2 diabetes clinical trial | 1 | 1 | Key clinical trial paper - only published human RCT specifically on THCV |
| 8 | Crossref/DOI verification | Verify DOIs for key THCV papers | 3 | 3 | DOI verification for key clinical and pharmacology papers |
| 9 | PubMed | tetrahydrocannabivarin THCV insulin sensitivity mouse model obesity ameliorates glucose | 1 | 1 | Key preclinical metabolic study (Cawthorne lab) directly on THCV in obesity models |
| 10 | WebSearch | THCV tetrahydrocannabivarin DEA scheduling legal status USA UK controlled substance | 10 | 2 | Legal status not available via PubMed; web search required |
| 11 | WebSearch | THCV first isolation discovery 1970 Gill Jones cannabis history | 10 | 2 | Historical discovery data not available through PubMed |
| 12 | PubMed | THCV default mode network fMRI resting state functional connectivity brain imaging | 1 | 1 | First human fMRI study of THCV - important for subjective effects and brain pharmacology |
| 13 | WebSearch | THCV pharmacokinetics oral dose humans half-life Cmax tmax | 10 | 2 | Specific THCV PK data not available through PubMed search; web retrieval needed |
77 claims by section — every cited sentence, checked against its source
pharmacology19 · 5 ok
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
At low-to-moderate concentrations, THCV acts as a potent, competitive CB1 receptor neutral antagonist — blocking CB1 agonist signaling without constitutively suppressing baseline receptor activitysupported
antagonizes CB1 agonists in CB1-expressing tissues (tissue- and ligand-dependent) sj.bjp.0707442
This neutral antagonism distinguishes THCV from the CB1 inverse agonist rimonabant, which suppresses constitutive CB1 activity below baseline and was withdrawn from clinical use due to depression and suicidality.supported
not rimonabant-like bph.12944
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
At higher doses in vivo (above approximately 5 mg/kg i.p. in mice), THCV transitions to CB1 partial agonism, producing THC-like effects including hypothermia, catalepsy, and hypolocomotionsupported
at higher doses in vivo can act as CB1 agonist sj.bjp.0707442
At CB2 receptors, THCV consistently functions as a partial agonistsupported
potent CB2 partial agonist in vitro sj.bjp.0707442
At CB2 receptors, THCV consistently functions as a partial agonistsupported
CB2 partial agonist bph.12944
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
safety13 · 2 ok
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
McPartland et al. (2014) explicitly concluded that THCV is very unlikely to produce rimonabant-like CNS adverse effects.supported
not rimonabant-like bph.12944
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
McPartland et al. (2014) noted that because THCV is not a CB1 inverse agonist and does not potentiate endocannabinoid tone, the abuse liability profile is expected to differ substantially from THCsupported
THCV is a high-affinity CB1 receptor ligand and potent antagonist in vitro; not rimonabant-like bph.12944
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
neuroscience8 · 1 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
This positions THCV within the theoretical framework of tonic vs. phasic endocannabinoid modulation: THCV may selectively blunt phasic endocannabinoid surges (such as those driving appetite in response to food cues) while preserving tonic signaling that maintains emotional homeostasis.supported
THCV is a high-affinity CB1 receptor ligand and potent antagonist in vitro; not rimonabant-like bph.12944
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
clinical-evidence7 · 0 ok
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
summary7 · 2 ok
Claim in summary — inconclusiveinconclusiveworking →
This two-carbon truncation produces a qualitatively distinct pharmacological profile: THCV functions as a neutral CB1 receptor antagonist at low-to-moderate doses and transitions to CB1 partial agonism only at higher doses, a dose-dependent switch that is pharmacologically unusual within the cannabinoid class.supported
antagonizes CB1 agonists in CB1-expressing tissues (tissue- and ligand-dependent); at higher doses in vivo can act as CB1 agonist sj.bjp.0707442
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
The 13-week clinical trial reported no serious adverse events, and THCV's classification as a neutral antagonist — rather than an inverse agonist like rimonabant — predicts a lower risk of depressogenic side effectssupported
not rimonabant-like bph.12944
comparative-pharmacology6 · 1 ok
The structural difference between THCV (C3 side chain) and Δ9-THC (C5 side chain) produces a pharmacological inversion at CB1: THC is a partial agonist across all doses, while THCV antagonizes CB1 at low-to-moderate doses and transitions to partial agonism only at higher doses (above approximately 5 mg/kg i.p. in mice)supported
antagonizes CB1 agonists in CB1-expressing tissues (tissue- and ligand-dependent); at higher doses in vivo can act as CB1 agonist sj.bjp.0707442
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
receptor-pharmacology6 · 1 ok
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
THCV, classified as a neutral antagonist, blocks agonist-induced signaling without suppressing constitutive activitysupported
THCV is a high-affinity CB1 receptor ligand and potent antagonist in vitro; not rimonabant-like bph.12944
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
chemistry4 · 1 ok
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
This two-carbon truncation is the defining structural difference and underlies THCV's substantially divergent receptor pharmacologysupported
antagonizes CB1 agonists in CB1-expressing tissues; at higher doses in vivo can act as CB1 agonist; potent CB2 partial agonist in vitro sj.bjp.0707442
history4 · 0 ok
pharmacokinetic-detail2 · 0 ok
effects-overview1 · 1 ok
Its closest functional comparator is not another cannabinoid but the withdrawn CB1 inverse agonist rimonabant — with the critical distinction that THCV's neutral antagonism avoids the depressogenic effects that ended rimonabant's clinical career.supported
not rimonabant-like; THCV is a high-affinity CB1 receptor ligand and potent antagonist in vitro; CB2 partial agonist bph.12944